Testosterone Screening in Military: Clinical Evidence & Endocrine Implications

The Military's Testosterone Screening Initiative: What the Science Actually Shows

The U.S. military's announced plan to screen servicemembers for low testosterone marks a significant shift in large-scale endocrine screening. Before we evaluate this policy through a clinical lens, we need to understand what the research actually demonstrates—and where the gaps exist.

Why Testosterone Screening Matters Clinically

Testosterone is not a simple binary marker. It operates within the hypothalamic-pituitary-gonadal (HPG) axis, a tightly regulated feedback system. Total testosterone, free testosterone, and bioavailable testosterone reflect different physiological states. Screening protocols that capture only total testosterone miss critical information.

The evidence is clear: symptomatic hypogonadism (persistently elevated LH/FSH with low testosterone, plus clinical symptoms like fatigue, mood disturbance, or sexual dysfunction) warrants investigation and potentially intervention. But asymptomatic populations with testosterone in the lower-normal range present a different clinical picture entirely.

The Screening Paradox: Prevalence vs. Clinical Significance

Studies show testosterone naturally declines ~1% annually after age 30. A 2013 meta-analysis in Endocrine Reviews found that roughly 20% of men over 60 have total testosterone <325 ng/dL—the traditional threshold. But only 2-3% meet diagnostic criteria for symptomatic hypogonadism.

This distinction matters operationally. Mass screening identifies a problem; it doesn't necessarily define who needs treatment. The challenge intensifies with military populations: are we measuring a physiological decline or a performance deficit?

Baseline Testing Protocol: What Should Actually Be Measured

If screening proceeds, this is what evidence-based testing requires:

Essential baseline labs:

• Total testosterone (morning draw, before 10 AM)
• Free testosterone (calculated or directly measured)
• LH and FSH (diagnostic of primary vs secondary hypogonadism)
• Estradiol (peripheral conversion and feedback effects)
• SHBG (sex hormone-binding globulin—critical for interpreting free T)
• TSH, T3, T4 (thyroid dysfunction mimics hypogonadism)
• Prolactin (elevated prolactin suppresses GnRH)
• DHEA-S (assesses adrenal axis status)
• HbA1c and fasting glucose (insulin resistance lowers SHBG, artificially raising free T)

A single total testosterone measurement is insufficient for diagnostic or treatment decisions.

Endocrine Consequences of Screening and Treatment

Here's where policy and physiology diverge. Testosterone replacement therapy (TRT) in eugonadal or low-normal men suppresses the HPG axis through negative feedback on GnRH. This occurs regardless of clinical benefit:

1. Exogenous testosterone inhibits LH and FSH production via suppression of GnRH at the hypothalamus and anterior pituitary.
2. Testicular function declines in men on sustained TRT without concurrent gonadotropin support.
3. Sperm production decreases significantly—relevant for military populations of reproductive age.
4. Dependency risk increases: once the HPG axis is suppressed, restarting endogenous testosterone production requires either high-dose HCG (human chorionic gonadotropin) or discontinuation with a multi-month recovery period.

For asymptomatic men with low-normal testosterone, the benefit-to-risk ratio remains undefined.

What the Literature on Asymptomatic Screening Shows

The Testosterone Trials (TTrials) published in NEJM (2016) showed that testosterone therapy improved sexual function and bone density in symptomatic men, but had minimal impact on strength or cognitive function. Importantly, it did not improve outcomes in men without hypogonadal symptoms.

For military readiness—the stated rationale—the evidence is thinner. Testosterone may modestly improve muscle mass and physical performance in deficient men, but only in the presence of concurrent resistance training. No evidence supports screening asymptomatic servicemembers to enhance performance.

Synergistic Considerations for HPG Axis Support

If screening identifies true hypogonadism, supporting natural testosterone production is preferable to suppressive replacement when possible. Evidence-based adjuncts include:

• Zinc (15-30 mg/day, as glycinate): co-factor for testosterone synthesis; deficiency suppresses LH
• Magnesium glycinate (400-500 mg/day): cofactor for 17β-HSD; improves sleep quality (testosterone peaks with sleep)
• Vitamin D3 (>2000 IU daily, target 50-60 ng/mL): epidemiological data links low D3 to low testosterone; mechanism involves VDR expression in testes
• Omega-3 (2-3g EPA/DHA daily): supports testicular Leydig cell function
• Ashwagandha (300-600 mg/day, withanolide-standardized): two RCTs show modest increases in testosterone and improved luteinizing hormone profiles

These are not performance drugs. They address nutritional deficits that impair endogenous production.

The Clinical Bottom Line

Large-scale testosterone screening in asymptomatic populations creates a false-positive problem: identifying men who fall outside reference ranges but suffer no functional impairment. It incentivizes treatment of normal variation rather than pathology.

If the military proceeds, the standard must be diagnostic—not screening alone:

1. Repeat testing of low-normal results (testosterone varies day-to-day)
2. Full HPG axis panel (LH, FSH, not just testosterone)
3. Assessment of actual symptoms (validated questionnaire, not assumption)
4. Baseline fertility labs for men of reproductive age
5. Consideration of modifiable drivers: sleep quality, stress/cortisol, body composition, micronutrient status

TRT is a powerful tool for symptomatic hypogonadism. It is not indicated for asymptomatic men with low-normal testosterone.

Disclaimer: This content is for educational purposes only and does not constitute medical advice.